Welcome to our dedicated page for IQVIA Holdings news (Ticker: $IQV), a resource for investors and traders seeking the latest updates and insights on IQVIA Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IQVIA Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IQVIA Holdings's position in the market.
Rhea-AI Summary
IQVIA Holdings Inc. reported a strong financial performance for the fourth quarter of 2023, with revenue reaching $3,868 million, GAAP Net Income of $469 million, and Adjusted EBITDA of $966 million. The company provided a full-year 2024 revenue guidance of $15,400 million to $15,650 million, showcasing positive growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
-
Rhea-AI Summary
IQVIA has been named to the Fortune World's Most Admired Companies list for the seventh consecutive year, earning the first-place ranking within the Health Care: Pharmacy and Other Services category for the third year in a row. The company also ranked number one in six categories for quality of management, people management, innovation, quality of products and services, global competitiveness, and use of corporate assets. Fortune's Most Admired Companies is a prestigious report card on corporate reputation, highlighting the business practices that make these companies highly regarded among their peers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. will release its fourth-quarter and full-year 2023 financial results on February 14, 2024. The management team will host a conference call and webcast. The earnings release and financial information will be posted on the IQVIA Investor Relations website. Interested parties can participate in the conference call by registering in advance. A replay of the webcast will be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
Rhea-AI Summary
The IQVIA Institute for Human Data Science report projects a 2 percentage point increase in growth outlook for global spending and demand for medicines, reaching approximately $2.3 trillion by 2028. This is driven by more patients getting access to new and better medicines, particularly in immunology, endocrinology, and oncology. The report also highlights lower expectations for COVID-19 vaccines and therapeutics, resulting in a $200 billion reduction in eight-year cumulative spending estimates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
-
Rhea-AI Summary
IQVIA (NYSE:IQV) has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category for its Digital Enablement division. The award recognizes outstanding achievement and innovation in healthcare marketing, with a focus on innovation, talent development, and social responsibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. (IQV) announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on November 29, 2023, at 10:50 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com, with a replay available later that day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
Rhea-AI Summary
IQVIA Holdings Inc. (NYSE:IQV) announces allocation of a new term B loan due 2031 of approximately $1,500 million, upsized due to lender demand. The loan, along with senior secured notes, will be used to repay existing loans and related fees. The Company also entered into a cross-currency swap agreement to hedge exposure to USD-denominated indebtedness, resulting in an effective net borrowing rate of 4.9015%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. (NYSE:IQV) announces the pricing of $1,250 million in senior secured notes due 2029, which was upsized due to strong demand. The proceeds will be used to repay outstanding term loans and pay fees and expenses related to the offering and credit agreement amendment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
-
Rhea-AI Summary
IQVIA Holdings Inc. (NYSE:IQV) Announces Intent to Raise $500 Million through Notes Offering and Amend Credit Facilities. The proceeds will be used to repay outstanding term loans and pay related fees and expenses. The offering is subject to market conditions and customary terms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.52%
Tags
Rhea-AI Summary
IQVIA, a global provider of data and analytics to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list. The list recognizes leaders who have made significant contributions to the industry and improved the lives of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
IQVIA Holdings Inc.
NYSE:IQV
IQV Rankings
IQV Stock Data
42.12B
179.80M
0.92%
92.3%
1.59%
Offices of All Other Miscellaneous Health Practitioners
Health Care and Social Assistance
United States of America
DURHAM
About IQV
quintiles and imshealth have merged together to form the new quintilesims. each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. quintilesims has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. as a global leader in protecting individual patient privacy, quintilesims uses healthcare data to deliver critical, real-world disease and treatment insights. to learn more, visit www.quintilesims.com